Home › Therapeutic areas › Neurology › Alzheimer's Disease

Alzheimer's Disease (14 companies)

Companies with an active program in Alzheimer's Disease.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ACIU AC Immune Neurology Rare 5 Phase 3 $210M 11
ABOS Acumen Pharmaceuticals Neurology 4 Phase 2 $16.6M 4
AXSM Axsome Therapeutics Neurology Rare 1 Approved $7.15B 15
CGTX Cognition Therapeutics Neurology 1 Phase 2 $59.9M 2
CYDY CytoDyn NeurologyOncology 1 Phase 2 $367M 3
GANX Gain Therapeutics MetabolicNeurology Rare 1 Phase 1 $52.5M 5
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 3 Phase 2 $236M 12
LGVN Longeveron CardiovascularNeurology Rare 1 Phase 2 $7.1M 3
MPLT MapLight Therapeutics Neurology 1 Phase 2 $365M 3
NRSN NeuroSense Therapeutics Neurology Rare 1 Phase 2 $2.9M 3
NAMS NewAmsterdam Pharma CardiovascularMetabolic+1 1 NDA Submitted $2.33B 6
PMN ProMIS Neurosciences Neurology Rare 2 Phase 1 $28.9M 9
TLSA Tiziana Life Sciences ImmunologyNeurology Rare 1 Phase 2 $83.2M 5
VYGR Voyager Therapeutics MetabolicNeurology Rare 2 Phase 1 $94.6M 9